Research and Clinical Trials

Brief Description  

The main purpose of this Phase II study is to determine whether the combination of MM-121(a fully human nonoclonal antibody) plus paclitaxel is more effective than paclitaxel alone based on Progression Free Survival (the length of time during and after treatment during which the disease does not get worse) in patients with advanced ovarian cancer resistant/refractory to platinum agents (cancer comes back less than 6 months after completing initial chemotherapy treatment).

Who may be Eligible  

Key inclusion criteria: Recurrent or persistant epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer. At least one prior platinum based chemotherapy regimen. Platinum-resistant or refractory to platinum therapy (disease progression during or within 6 months after completing platinum therapy). Willing to undergo pretreatment biopsy. Adequate blood counts, kidney and liver function.

IRB Number  

02-12-06A

Principal Investigator  

Naumann, Wendel

For More Information, Contact  Sarah  , Norek
Phone:  (704) 355-1520  Fax:  (704) 355-9897  
Email:  Sarah.Norek@atriumhealth.org
Address:Blumenthal Cancer Center 1025 Morehead Medical Drive Suite 600 Charlotte, NC 28204